ATTAIN-1 Trial Explained: What Orforglipron’s Phase 3 Data Actually Shows
Key Takeaways
- Clinically Significant Weight Loss: In the 72-week ATTAIN-1 trial, patients taking the highest dose (36 mg) of orforglipron achieved a mean weight loss of 11.2% to 12.4%, compared to just 2.1% with placebo.
- High Responder Rates: Approximately 55-60% of participants on the 36 mg dose lost at least 10% of their body weight, a threshold widely considered clinically meaningful for improving health outcomes.
- Cardiometabolic Benefits: Beyond weight loss, orforglipron led to significant improvements, including a 10 cm reduction in waist circumference and a 5 to 6 mmHg drop in systolic blood pressure compared to placebo.
- Expected GLP-1 Side Effects: The safety profile was consistent with the GLP-1 agonist class, with the most common side effects being gastrointestinal (nausea, diarrhea, vomiting), leading to a 5-10% discontinuation rate.
Foundayo (orforglipron) recently received FDA approval. Naturally, patients and clinicians alike want to understand the science behind it. The ATTAIN-1 trial, a major Phase 3 study published in the New England Journal of Medicine, is the foundation of this approval. This study gives us the strongest evidence we have on how well and how safely this new, once-daily oral GLP-1 agonist works. And trust me, understanding these results is essential for setting realistic expectations and making smart treatment decisions.
So, what does the data really tell us? In this article, I want to really dig into the ATTAIN-1 study. We’ll break down the orforglipron weight loss results, look at the cardiometabolic benefits, and put all this data into context for the future of obesity management. We’re not just looking at averages; we’ll explore the full range of outcomes that define this new option.
Dissecting the ATTAIN-1 Trial Design
Before we interpret any clinical trial results, we first have to understand how the study was actually done. ATTAIN-1 was a randomized, double-blind, placebo-controlled trial. In medical research, that’s the gold standard. They enrolled 3,127 adults from nine different countries. All of them had either obesity (BMI ≥30) or were overweight (BMI ≥27) with at least one weight-related health condition, like high blood pressure or high cholesterol.
Here’s the thing: this group specifically did not have type 2 diabetes. Why does that matter? It allowed the researchers to isolate the drug’s effect purely on weight management. Participants started with a mean BMI of 37 to 38, and about 64% were women. A good, diverse group, in my experience.
Participants were randomly assigned to get one of three doses of orforglipron (6 mg, 12 mg, or 36 mg) or a placebo. They took their assigned pill once a day for 72 weeks. Every single group also received diet and exercise counseling. This was important; it made sure we measured the drug’s effect as an *addition* to lifestyle changes. The primary endpoint—the main question they wanted to answer—was the percentage change in body weight from the start of the study to week 72. This comprehensive design, with so many people, a long duration, and a placebo control, really gives us high-quality evidence to assess orforglipron’s true impact.
The Primary Endpoint: Orforglipron Weight Loss Results in Detail
The headline from the ATTAIN-1 trial? Orforglipron produced significant, dose-dependent weight loss. At 72 weeks, patients on the highest dose (36 mg) saw their mean body weight drop by 11.2% to 12.4%. That’s a big number. The placebo group, even with diet and exercise, lost only 2.1% of their body weight. So, for the high-dose orforglipron group, we’re talking about an average loss of roughly 27 pounds (12.4 kg). Even the lower doses worked well, with the 6 mg and 12 mg groups losing about 7.5% and 8.4% on average, respectively.
But averages don’t tell the whole story. I always want to know how many individuals actually hit meaningful weight loss goals. That’s where the “responder analysis” comes in. For the 36 mg dose:
- ≥10% Weight Loss: 55-60% of participants hit this goal. Compare that to just 13% in the placebo group. This is a big deal, as a 10% weight loss is linked to real improvements in cardiometabolic risk factors.
- ≥15% Weight Loss: 36-40% of participants reached this higher threshold (vs. 6% on placebo).
- ≥20% Weight Loss: Nearly one in five participants (19%) lost at least 20% of their body weight (vs. 3% on placebo).
These orforglipron clinical trial results show a clear and substantial effect on body weight. It’s far beyond what lifestyle changes alone can achieve. This confirms its effectiveness for chronic weight management.
Beyond the Scale: Cardiometabolic Improvements
As a physician, I know effective obesity treatment isn’t just about the number on the scale. It’s about improving overall health. The ATTAIN-1 trial looked at several other important measures. And it revealed orforglipron’s very positive impact on cardiometabolic health. Patients taking the 36 mg dose, for example, saw their waist circumference shrink by a mean of 10 cm. That’s significantly more than the 3 cm reduction we saw with placebo.
This matters because waist circumference is a strong indicator of visceral fat. That’s the metabolically active fat around our internal organs, and it’s heavily linked to health risks. What else did we see? Orforglipron had good effects on blood pressure and lipids. Systolic blood pressure dropped by 5 to 6 mmHg more than with placebo, which is a reduction that can genuinely lower cardiovascular risk. And yes, there were also significant improvements in lipid profiles, with good reductions in triglycerides, non-HDL cholesterol, and LDL-C (“bad” cholesterol). Even though this study population didn’t have diabetes, we still saw modest improvements in markers of insulin resistance, like fasting glucose and HOMA-IR. These findings really show that the weight loss from orforglipron brings with it concrete improvements in the key factors that drive cardiovascular and metabolic disease.
Safety, Tolerability, and Clinical Context
Let me be direct about this: no medication is without side effects. Orforglipron’s safety profile is quite typical for the GLP-1 receptor agonist class. The most common issues reported were gastrointestinal. Nausea was the big one, affecting 29-36% of participants on the active drug, compared to about 10% on placebo. Diarrhea, vomiting, and abdominal discomfort also popped up. Usually, these side effects were mild to moderate. They also tended to happen when the dose was first being increased. Still, they were significant enough to make about 5-10% of patients on orforglipron stop the trial, versus 3% in the placebo group.
How do we put these orforglipron weight loss results into perspective with other treatments out there? Its mean weight loss of around 11-12% is a bit less than the roughly 15% we see with injectable semaglutide (Wegovy) or the 15-17% from high-dose oral semaglutide. And it’s also lower than the 20-21% achieved with injectable tirzepatide (Zepbound). But here’s the kicker: orforglipron is a non-peptide, small-molecule drug. What does that mean for you? It means you can take it as a simple daily pill without all the strict fasting and water intake rules of oral semaglutide. That makes it much easier to stick with, which is huge for patients.
For many of my patients, achieving a clinically meaningful 12 percent weight loss with a convenient daily tablet will be a very appealing and effective treatment plan. It’s a new tool in our toolbox, and that’s always a good thing.
References
- Wharton S et al. “Orforglipron for Weight Management in Adults with Obesity.” NEJM 2026 (ATTAIN-1 trial).
- Jastreboff AM et al. “Tirzepatide Once Weekly for the Treatment of Obesity.” NEJM 2022 (SURMOUNT-1).
- Wadden TA et al. “Oral Semaglutide for Obesity.” NEJM 2025 (OASIS-4).
- Wilding JPH et al. “Once-Weekly Semaglutide in Adults with Overweight or Obesity.” NEJM 2021 (STEP-1).
Sources
- Wharton S, Aronne LJ, Stefanski A, et al. Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment. New England Journal of Medicine, 2025. PMID: 40960239. doi:10.1056/NEJMoa2511774
- Santulli G. From needles to pills: oral GLP-1 therapy enters the obesity arena. Cardiovascular Diabetology Endocrinology Reports, 2025. PMID: 41053816. doi:10.1186/s40842-025-00245-5
- Xie Z, Zheng G, Liang Z, et al. Seven GLP-1 receptor agonists and polyagonists for weight loss in patients with obesity or overweight: an updated systematic review and network meta-analysis of randomized controlled trials. Metabolism, 2024. PMID: 39305981. doi:10.1016/j.metabol.2024.156038
- Kokkorakis M, Chakhtoura M, Rhayem C, et al. Emerging pharmacotherapies for obesity: A systematic review. Pharmacological Reviews, 2025. PMID: 39952695. doi:10.1124/pharmrev.123.001045
This is not personal medical advice. See our medical disclaimer and editorial standards.
Licensed physician and clinical AI specialist. Founder and Editor-in-Chief of ZayedMD, a physician-led medical publication covering clinical AI, neurology, metabolic health, and evidence-based patient guidance.
